StockData
Climb Bio, Inc. logo

Climb Bio, Inc. (CLYM) stock

CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$9.78−0.16 (-1.61%)

Close on Nov 17, 2026Market cap $561.73MP/E –Yield –

Climb Bio operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Climb Bio's operating cash flow for the twelve months ending Jun 30, 2026 was -$52.70M. For fiscal 2025 it was -$54.36M. The highest annual figure on record is -$14.10M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$54.36M–
FY2024Dec 31, 2024-$15.56M–
FY2023Dec 31, 2023-$20.60M–
FY2022Dec 31, 2022-$37.37M–
FY2021Dec 31, 2021-$36.07M–
FY2020Dec 31, 2020-$14.10M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$10.55M–
Q1 FY2026Mar 31, 2026-$14.38M–
Q4 FY2025Dec 31, 2025-$15.64M–
Q3 FY2025Sep 30, 2025-$12.14M–
Q2 FY2025Jun 30, 2025-$11.15M–
Q1 FY2025Mar 31, 2025-$15.43M–
Q4 FY2024Dec 31, 2024-$5.52M–
Q3 FY2024Sep 30, 2024-$7.56M-316.5%
Q2 FY2024Jun 30, 2024-$667.00K–
Q1 FY2024Mar 31, 2024-$1.82M–
Q4 FY2023Dec 31, 2023-$947.00K–
Q3 FY2023Sep 30, 2023$3.49M–
Q2 FY2023Jun 30, 2023-$7.97M–
Q1 FY2023Mar 31, 2023-$15.18M–
Q4 FY2022Dec 31, 2022-$8.45M–
Q3 FY2022Sep 30, 2022-$4.18M–
Q2 FY2022Jun 30, 2022-$13.97M–
Q1 FY2022Mar 31, 2022-$10.78M–
Q4 FY2021Dec 31, 2021-$7.88M–
Q3 FY2021Sep 30, 2021-$12.97M–
Q2 FY2021Jun 30, 2021-$8.48M–
Q1 FY2021Mar 31, 2021-$6.74M–
Q4 FY2020Dec 31, 2020-$5.62M–
Q3 FY2020Sep 30, 2020-$2.38M–

More Climb Bio figures

See a number that looks wrong?